To provide additional clinical perspective on the SURPASS-ET findings, Oncology Brothers hosted a dedicated podcast discussion with Dr. John Mascarenhas, a recognized MPN specialist from Mount Sinai. During the episode, Dr. Mascarenhas shared his clinical perspective on the FDA approval of ropeginterferon alfa-2b for essential thrombocythemia, the design and outcomes of the SURPASS-ET study, and how the treatment compares with anagrelide.

The conversation also explored disease modification, JAK2 allele burden, treatment dosing, management of adverse effects, and considerations for younger patients. By bringing an MPN specialist into an in-depth discussion of the latest clinical evidence, the podcast provides healthcare professionals and other interested readers with an additional expert perspective on the evolving treatment landscape of essential thrombocythemia.